Discovery Labs announced yesterday that it has gained FDA approval for Surfaxin, a surfactant treatment for respiratory distress syndrome in infants. Discovery Labs anticipates launching Surfaxin commercially in the U.S. late this year.
“The approval of SURFAXIN is an important medical advancement for the neonatology community and parents of preterm infants who will soon have an effective alternative to animal-derived surfactants to prevent the development of RDS,” said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. “This is a significant milestone in our continuing efforts to develop a pipeline of products to further advance the standard of respiratory critical care.”
Investors, meanwhile, liked the news and drove the company’s shares up 35% in extended trading, as noted by Reuters.
To learn more about pediatric drugs, check out the World Pediatric Drugs Congress, taking place in the D.C. area this coming April.